Project Details
Project Description
CGRP monoclonal antibodies are an effective new preventative treatment for chronic migraine, however given the multiple biological functions of CGRP, an off-target effect of its inhibition is possible. In 2021, the group published a series of possible inflammatory complications following administration of the medication. This project is designed to further explore the effect of CGRP mAbs by evaluating the cytokine profile of patients pre/post administration.
Status | Active |
---|---|
Effective start/end date | 1/02/23 → … |